Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Declares $.07 Dividend; ViaCell Deal Clears Waiting Period

NEW YORK (GenomeWeb News) — PerkinElmer’s bid to buy ViaCell has passed the Hart-Scott-Rodino antitrust waiting period, which expired yesterday.
 
Separately today, PerkinElmer declared a $.07 quarterly dividend payable on Feb. 8, 2008, to all stockholders of record at the end of Jan. 18, 2008.
 
The company is scheduled to release its quarterly earnings after the close of trading today.
 
PerkinElmer said in early October it plans to spend $300 million to buy Viacell, a Massachusetts-based company that collects and preserves umbilical cord stem cells for later use.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.